Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Vlado Perkovic(New South Wales Department of Health), Kenneth W. Mahaffey(Cardiovascular Institute of the South), Tom Greene(University Medical Center Groningen), Carol A. Pollock(The University of Sydney), Christopher P. Cannon(Brigham and Women's Hospital), Hiddo J.L. Heerspink(University Medical Center Groningen), Séverine Bompoint(Royal North Shore Hospital), Yshai Yavin(Royal North Shore Hospital), Dick de Zeeuw(University Medical Center Groningen), Adeera Levin(University of British Columbia), Rajiv Agarwal(Richard L. Roudebush VA Medical Center), David C. Wheeler(University College London), Bruce Neal(UNSW Sydney), David M. Charytan(NYU Langone Health), Scott Bull(Royal North Shore Hospital), Pei-Ling Chu(Royal North Shore Hospital), Bernard Zinman(Mount Sinai Hospital), George Capuano(Royal North Shore Hospital), Hong Zhang(University of Hawaiʻi at Mānoa), Robert Edwards(Royal North Shore Hospital), Meg Jardine(Royal North Shore Hospital), George L. Bakris(Pennsylvania State System of Higher Education), Gary Meininger(Royal North Shore Hospital), Barry M. Brenner(Brigham and Women's Hospital)
Cited by 5,966
Related Papers
A New Equation to Estimate Glomerular Filtration Rate
|Annals of Internal Medicine|2009|25.7k
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
|Hypertension|2003|13.3k
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
|New England Journal of Medicine|2015|11.9k
K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification
|Data Archiving and Networked Services (DANS)|2002|11.7k
Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019
|Journal of the American College of Cardiology|2020|11.1k